1. AB0445 Exposure–Efficacy Analysis of Mavrilimumab in Rheumatoid Arthritis: Modeling and Simulation of Phase II Clinical Data. (9th June 2015) Authors: Jin, D.C.; Wu, C.-Y.; Roskos, L.K.; Godwood, A.; Close, D.; Wang, B. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 1043 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0167 Patient-Reported Outcomes (PROS) During Treatment with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GM–CSFR-Alpha, In the Phase IIB Earth Explorer 1 Study. (9th June 2015) Authors: Kremer, J.M.; Burmester, G.R.; Weinblatt, M.; Williams, A.E.; Karlsson, N.; Godwood, A.; Albulescu, M.; Close, D. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 483 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0216 Long-Term Safety and Efficacy of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, in Patients with Rheumatoid Arthritis. (15th July 2016) Authors: Burmester, G.; McInnes, I.; Kremer, J.; Miranda, P.; Vencovský, J.; Godwood, A.; Albulescu, M.; Close, D.; Weinblatt, M. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 510 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0232 Consistent efficacy and safety outcomes between european and japanese subjects with rheumatoid arthritis following treatment with mavrilimumab in the phase 2 earth study. (23rd January 2014) Authors: Burmester, G.; Takeuchi, T.; Barbarash, O.; Ranganna, G.; Close, D.; Godwood, A.; Saurigny, D. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A451 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP0034 Efficacy and Safety of Mavrilimumab, A Fully Human Gm–CSFR-Alpha Monoclonal Antibody in Patients with Rheumatoid Arthritis: Primary Results from the Earth Explorer 1 Study. (9th June 2015) Authors: Burmester, G.R.; McInnes, I.B.; Kremer, J.M.; Miranda, P.; Korkosz, M.; Vencovsky, J.; Rubbert-Roth, A.; Mysler, E.; Sleeman, M.A.; Godwood, A.; Albulescu, M.; Close, D.; Weinblatt, M. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OP0244 Sustained Suppression of Rheumatoid Arthritis Disease Markers by Mavrilimumab but Not Golimumab in Anti-Tumor Necrosis Factor-Inadequate Responders: An Exploratory Analysis in The Phase IIB Earth Explorer 2 Clinical Trial. (15th July 2016) Authors: Guo, X.; Wang, S.; Bay-Jensen, A.C.; Karsdal, M.A.; Godwood, A.; Close, D.; Ryan, P.C.; Roskos, L.K.; White, W.I. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 150 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. SAT0146 Earth Explorer 2, A Phase IIB Exploratory Study Evaluating Efficacy and Safety of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, and The Tumor Necrosis Factor Antagonist Golimumab in Rheumatoid Arthritis. (15th July 2016) Authors: Weinblatt, M.; McInnes, I.; Kremer, J.; Miranda, P.; Vencovský, J.; Godwood, A.; Albulescu, M.; Close, D.; Burmester, G. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 717 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. SAT0189 Rapid Onset of Clinical Benefit in Patients with RA Treated with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GM–CSFR-ALPHA: Subanalysis of the Phase IIB Earth Explorer 1 Study. (9th June 2015) Authors: McInnes, I.B.; Burmester, G.R.; Kremer, J.M.; Miranda, P.; Korkosz, M.; Vencovsky, J.; Rubbert-Roth, A.; Mysler, E.; Close, D.; Sleeman, M.; Godwood, A.; Albulescu, M.; Weinblatt, M. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 723 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. SAT0260 Biomarkers Associated with Rheumatoid Arthritis Disease Activity Including Joint Damage Correlate with Changes in Clinical Response in Subjects Treated with Mavrilimumab at Doses above 10 Mg. (10th June 2014) Authors: White, W.; Ryan, P.C.; Guo, X.; Sinibaldi, D.; Ranganna, G.; Godwood, A.; Saurigny, D.; Close, D.; Eck, S.; Wilkins, D.; Roskos, L.; Sleeman, M.; Li, W.; Cavet, G.; Defranoux, N. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 687 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗